Marinomed Signs Collaboration with Boehringer Ingelheim for Anti-Viral Nasal Spray Against Common Cold
Marinomed Biotechnologie GmbH announced that it has signed a licensing agreement with Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed’s anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia. This nasal spray is based on Marinomed’s anti-viral respiratory technology platform mavirex. Marinomed will receive an upfront payment in the million EUR range from Boehringer Ingelheim, in addition to payments upon the achievement of certain market entry milestones and royalties. Further financial details were not disclosed.
Dr. Thomas Friedrich, CFO of Marinomed, said: “This is a landmark agreement for Marinomed. We are delighted to commence a long-term collaboration with Boehringer Ingelheim, a perfect partner for the successful marketing of our innovative common cold product worldwide.”
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.